Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AZD8233 in Renal Impairment
NCT05065463Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD8233 in hypercholesterolemia (3 arms), sponsored by AstraZeneca. Primary endpoints: Observed maximum plasma concentration at Day 90, Area under the plasma concentration-time curve from time zero extrapolated to infinity at Day 90 and 6 more. Started Aug 2022; status: terminated.
02
Drugs
AZD8233
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05065463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065463.